Skip to content
← All treatment topics

TREATMENT READING

Hairy Cell Leukemia

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

27 sections
  1. Treatment of Hairy Cell Leukemia
  2. Treatment Options for Hairy Cell Leukemia
  3. Cladribine with or without rituximab
  4. BRAF inhibitors (vemurafenib or dabrafenib) with or without rituximab or trametinib
  5. Rituximab
  6. Pentostatin
  7. Ibrutinib
  8. Re-treatment with cladribine or pentostatin
  9. Bendamustine with rituximab
  10. Splenectomy
  11. Interferon
  12. Certain factors affect treatment options and prognosis (chance of recovery).
  13. Sometimes hairy cell leukemia does not respond to treatment or comes back after treatment.
  14. Treatment Option Overview
  15. Key Points
  16. There are different types of treatment for patients with hairy cell leukemia.
  17. The following types of treatment are used:
  18. Watchful waiting
  19. Chemotherapy
  20. Targeted therapy
  21. Surgery
  22. New types of treatment are being tested in clinical trials.
  23. Treatment for hairy cell leukemia may cause side effects.
  24. Patients may want to think about taking part in a clinical trial.
  25. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  26. Follow-up care may be needed.
  27. Treatment of Hairy Cell Leukemia

Health professional

Treatment of Hairy Cell Leukemia

Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 21, 2025. Captured 2026-09-09.

Hairy cell leukemia is highly treatable but rarely cured. Because it is easily controlled, many patients have prolonged survival with the use of sequential therapies. The decision to treat is based on signs of disease progression, including any of the following factors:

Cytopenias (especially if symptomatic).

Increasing splenomegaly.

The presence of other, usually infectious, complications.

If the patient is asymptomatic and if blood counts are maintained in an acceptable range, therapy may not be needed.[1]

Sources: 1

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment of Hairy Cell Leukemia

Treatment Options for Hairy Cell Leukemia

Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 21, 2025. Captured 2026-09-09.

Prior to the COVID-19 (SARS-CoV-2) pandemic, the standard initial therapy for patients with hairy cell leukemia was infusion of cladribine daily for 5 days, given with or without eight weekly doses of rituximab.[2-4] However, treatment with a purine analogue–based regimen led to significant and prolonged neutropenia and impairment of T-cell function, which were both problematic during the pandemic in fighting viral infection and establishing vaccination-induced immunity.

Sources: 2 · 4

Other options for initial standard therapy, instead of cladribine or pentostatin, may offer less toxicity in terms of infection and long-term risk of secondary malignancies. However, these options may provide less durable response.

The Hairy Cell Leukemia Foundation convened a virtual meeting of 39 experts from around the world to amend the 2017 consensus recommendations.[5] The adapted treatment guidelines, published in 2021, are based primarily on anecdotal experience and expert opinion, as controlled trials for this indolent leukemia cannot be completed expeditiously given the low incidence of this disease.[6][Level of evidence C3] The adapted treatment guidelines are summarized below.

Sources: 5 · 6 · Level of evidence C3

Consider watchful waiting when feasible; asymptomatic patients with noncritical levels of pancytopenia can be monitored closely.

Cladribine, with or without rituximab,[4] remains the standard of care. However, due to the risk of serious and prolonged immunosuppression, nonchemotherapy treatment options may be preferable for older, frail patients with higher risk of infection (or for those who have active infections).

Sources: 4

BRAF inhibitors such as vemurafenib, dabrafenib, or encorafenib are nonchemotherapeutic options that can be combined with rituximab or obinutuzumab.[7-10] Most patients with hairy cell leukemia have BRAF pathogenic variants, but this should be verified by flow cytometry. Despite extensive experience with vemurafenib for patients with relapsed disease, the U.S. Food and Drug Administration (FDA) has not approved oral vemurafenib for patients with hairy cell leukemia.

Sources: 7 · 10

Consider using rituximab alone intravenously (IV) for 4 to 8 weeks or in combination with a BRAF inhibitor.[11] Anti-CD20 monoclonal antibodies can impair future vaccine response, but they do not affect immunity from prior vaccination.

Sources: 11

In patients with relapsed disease, the previously mentioned options are available, along with ibrutinib (the Bruton tyrosine kinase inhibitor).[12]

Sources: 12

Treatment options for hairy cell leukemia include:

Watchful waiting, if feasible.

Cladribine with or without rituximab.

Sources: Cladribine with or without rituximab

BRAF inhibitors (vemurafenib or dabrafenib) with or without rituximab or trametinib.

Sources: BRAF inhibitors (vemurafenib or dabrafenib) with or without rituximab or trametinib

Rituximab.

Sources: Rituximab

Pentostatin.

Sources: Pentostatin

Ibrutinib.

Sources: Ibrutinib

Re-treatment with cladribine or pentostatin.

Sources: Re-treatment with cladribine or pentostatin

Bendamustine with rituximab.

Sources: Bendamustine with rituximab

Splenectomy.

Sources: Splenectomy

Interferon.

Sources: Interferon

Health professional · Treatment of Hairy Cell Leukemia / Treatment Options for Hairy Cell Leukemia

Cladribine with or without rituximab

Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 21, 2025. Captured 2026-09-09.

Cladribine may be given with or without rituximab to treat hairy cell leukemia.

Evidence (cladribine with or without rituximab):

In a phase II study, 68 patients with previously untreated hairy cell leukemia were randomly assigned to receive cladribine (0.15 mg/kg IV) on days 1 to 5, with eight weekly doses of rituximab either concurrently (starting on day 1) or delayed (starting after 6 months of cladribine treatment) if still positive with measurable residual disease (MRD) testing.[4][Level of evidence C3]

Sources: 4 · Level of evidence C3

In a phase II study, 68 patients with previously untreated hairy cell leukemia were randomly assigned to receive cladribine (0.15 mg/kg IV) on days 1 to 5, with eight weekly doses of rituximab either concurrently (starting on day 1) or delayed (starting after 6 months of cladribine treatment) if still positive with measurable residual disease (MRD) testing.[4][Level of evidence C3]

With a median follow-up of 96 months, 94% of patients who received concurrent therapy were MRD-free, compared with 12% of patients who received delayed therapy.

Although patients who underwent concurrent therapy had more need for platelet transfusions, they demonstrated higher neutrophil and platelet counts after 1 month.

A retrospective case series reported a median progression-free survival (PFS) of 67 months in patients with relapsed disease who received a purine nucleoside analogue (usually cladribine) plus rituximab.[13][Level of evidence C2]

Sources: 13 · Level of evidence C2

A retrospective case series of nine patients with a histologic variation of hairy cell leukemia (HCL-v) reported an 88% complete response rate and 3-year PFS rate of 42% (95% confidence interval [CI], 1%–84%) after treatment with a purine nucleoside analogue (usually cladribine) plus rituximab.[14][Level of evidence C2]

Sources: 14 · Level of evidence C2

Cladribine was given by daily subcutaneous injections or by daily 2-hour IV infusions for 5 to 7 days.[5,15-17][Level of evidence C3] Purine analogues should be avoided in cases of active infection or moderate to severe hepatic or renal impairment.

Sources: 5 · 15 · 17 · Level of evidence C3

Cladribine was given by daily subcutaneous injections or by daily 2-hour IV infusions for 5 to 7 days.[5,15-17][Level of evidence C3] Purine analogues should be avoided in cases of active infection or moderate to severe hepatic or renal impairment.

The complete response rate was 50% to 80%.

The overall response rate was 85% to 95%.

A National Cancer Institute group C protocol of 979 patients treated with cladribine reported lower response rates (i.e., 50% complete remission rate, 37% partial remission rate) compared with other studies.[18] Responses were durable in patients treated with a short course of cladribine, and patients who had a relapse often responded to re-treatment with cladribine.[2,13,19]

Sources: 18 · 2 · 13 · 19

A retrospective review included 83 patients, aged 40 years and younger.[2]

Sources: 2

A retrospective review included 83 patients, aged 40 years and younger.[2]

The median time to first relapse was 54 months for all responders, and the median overall survival (OS) was 21 years from diagnosis.

Cladribine may cause fever and immunosuppression; documented infection was found in 33% of treated patients.

In a retrospective study of patients with cladribine-associated neutropenic fever, filgrastim (G-CSF) did not reduce the percentage of febrile patients, number of febrile days, or frequency of hospital admissions to receive antibiotics.[3]

Sources: 3

Health professional · Treatment of Hairy Cell Leukemia / Treatment Options for Hairy Cell Leukemia

BRAF inhibitors (vemurafenib or dabrafenib) with or without rituximab or trametinib

Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 21, 2025. Captured 2026-09-09.

BRAF V600E pathogenic variants are found in almost 100% of patients with classic-form hairy cell leukemia and almost never found in patients with other B-cell lymphomas and leukemias, including HCL-v.[20][Level of evidence C3] Vemurafenib or other BRAF inhibitors such as dabrafenib can be given with rituximab or obinutuzumab.[10,21] The FDA has not approved BRAF inhibitors for hairy cell leukemia, but they can be used off-label in clinical practice.[22]

Sources: 20 · Level of evidence C3 · 10 · 21 · 22

Evidence (vemurafenib with or without rituximab):

Several multicenter studies evaluated vemurafenib, given orally alone for 4 months or orally for 2 months with rituximab infused in eight doses over 18 weeks, in patients with relapsed or refractory hairy cell leukemia.[7,8,10,23][Level of evidence C3]

Sources: 7 · 8 · 10 · 23 · Level of evidence C3

Several multicenter studies evaluated vemurafenib, given orally alone for 4 months or orally for 2 months with rituximab infused in eight doses over 18 weeks, in patients with relapsed or refractory hairy cell leukemia.[7,8,10,23][Level of evidence C3]

After a median follow-up of 23 to 40 months, for the 86 patients treated with vemurafenib alone, the following was reported in two studies:[7,8,23][Level of evidence C3]

Sources: 7 · 8 · 23 · Level of evidence C3

Several multicenter studies evaluated vemurafenib, given orally alone for 4 months or orally for 2 months with rituximab infused in eight doses over 18 weeks, in patients with relapsed or refractory hairy cell leukemia.[7,8,10,23][Level of evidence C3] › After a median follow-up of 23 to 40 months, for the 86 patients treated with vemurafenib alone, the following was reported in two studies:[7,8,23][Level of evidence C3]

The overall response rate was 86% to 98%.

The complete response rate was 33% to 38%.

The median treatment-free survival was 18 to 25 months.

Retreatment at relapse resulted in an 86% response rate, and the median relapse-free survival was 12.7 months in one of the trials, with a 40-month median follow-up.[23][Level of evidence C2]

Sources: 23 · Level of evidence C2

Several multicenter studies evaluated vemurafenib, given orally alone for 4 months or orally for 2 months with rituximab infused in eight doses over 18 weeks, in patients with relapsed or refractory hairy cell leukemia.[7,8,10,23][Level of evidence C3]

After a median follow-up of 37 months, for the 30 patients treated with vemurafenib plus rituximab, the following was reported:[10][Level of evidence C3]

Sources: 10 · Level of evidence C3

Several multicenter studies evaluated vemurafenib, given orally alone for 4 months or orally for 2 months with rituximab infused in eight doses over 18 weeks, in patients with relapsed or refractory hairy cell leukemia.[7,8,10,23][Level of evidence C3] › After a median follow-up of 37 months, for the 30 patients treated with vemurafenib plus rituximab, the following was reported:[10][Level of evidence C3]

The complete response rate was 87%.

The PFS rate was 78% at 37 months.

In patients who had a complete response, 65% had no MRD.

Evidence (dabrafenib plus trametinib):

In a phase II trial of patients with relapsed or refractory disease, 55 patients received dabrafenib and trametinib orally until their disease progressed, they experienced unacceptable toxicity, or death occurred.[24]

Sources: 24

In a phase II trial of patients with relapsed or refractory disease, 55 patients received dabrafenib and trametinib orally until their disease progressed, they experienced unacceptable toxicity, or death occurred.[24]

With a median follow-up of 43.2 months, the overall response rate was 89.0% (95% CI, 77.8%–95.9%), the complete response rate was 65.5%, the 2-year PFS rate was 94.5%, and the 2-year OS rate was 95.5%.[24][Level of evidence C1]

Sources: 24 · Level of evidence C1

Health professional · Treatment of Hairy Cell Leukemia / Treatment Options for Hairy Cell Leukemia

Rituximab

Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 21, 2025. Captured 2026-09-09.

Rituximab can induce durable remissions (with minimal toxic effects), but rarely complete remissions, in patients with multiple relapses or refractory disease after treatment with a purine analogue or interferon.[11,22,25][Level of evidence C3]

Sources: 11 · 22 · 25 · Level of evidence C3

Health professional · Treatment of Hairy Cell Leukemia / Treatment Options for Hairy Cell Leukemia

Pentostatin

Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 21, 2025. Captured 2026-09-09.

Pentostatin given IV every other week for 3 to 6 months produced a 50% to 76% complete response rate and an 80% to 87% overall response rate.[26] Complete remissions were of substantial duration. Purine analogues should be avoided in cases of active infection or moderate to severe hepatic or renal impairment.

Sources: 26

Evidence (pentostatin):

Two trials reported results on the 9-year median follow-up of patients treated with pentostatin.[27,28]

Sources: 27 · 28

Two trials reported results on the 9-year median follow-up of patients treated with pentostatin.[27,28]

The relapse-free survival rates ranged from 56% to 67%.

Side effects included fever, immunosuppression, cytopenias, and renal dysfunction.

A randomized trial compared pentostatin to recombinant interferon alfa-2a.[26]

Sources: 26

A randomized trial compared pentostatin to recombinant interferon alfa-2a.[26]

Pentostatin demonstrated higher response rates and more durable responses.

Health professional · Treatment of Hairy Cell Leukemia / Treatment Options for Hairy Cell Leukemia

Ibrutinib

Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 21, 2025. Captured 2026-09-09.

Ibrutinib, a tyrosine kinase inhibitor, has been studied in the treatment of hairy cell leukemia.

Evidence (ibrutinib):

In a phase II study, 37 patients with refractory hairy cell leukemia were treated with ibrutinib. The median follow-up was 42 months.[29][Level of evidence C3]

Sources: 29 · Level of evidence C3

In a phase II study, 37 patients with refractory hairy cell leukemia were treated with ibrutinib. The median follow-up was 42 months.[29][Level of evidence C3]

The response rate was 54%.

The estimated 36-month PFS rate was 73%.

The OS rate was 85%.

Health professional · Treatment of Hairy Cell Leukemia / Treatment Options for Hairy Cell Leukemia

Re-treatment with cladribine or pentostatin

Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 21, 2025. Captured 2026-09-09.

Patients with hairy cell leukemia who have a relapse after the first course of cladribine or pentostatin often respond well to re-treatment with the same or another purine analogue, especially if relapse occurs after several years.[13][Level of evidence C3]

Sources: 13 · Level of evidence C3

Health professional · Treatment of Hairy Cell Leukemia / Treatment Options for Hairy Cell Leukemia

Bendamustine with rituximab

Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 21, 2025. Captured 2026-09-09.

Evidence (bendamustine with rituximab):

A phase II study evaluated 12 patients with relapsed or refractory disease, three of whom were negative for BRAF variants. Patients received the combination of bendamustine and rituximab.[30]

Sources: 30

A phase II study evaluated 12 patients with relapsed or refractory disease, three of whom were negative for BRAF variants. Patients received the combination of bendamustine and rituximab.[30]

The overall response rate was 100%, and the complete remission rate was 50%.[30][Level of evidence C3]

Sources: 30 · Level of evidence C3

Health professional · Treatment of Hairy Cell Leukemia / Treatment Options for Hairy Cell Leukemia

Splenectomy

Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 21, 2025. Captured 2026-09-09.

Splenectomy plays a decreasing role in treating hairy cell leukemia because effective alternatives are available. Splenectomy will partially or completely normalize the peripheral blood in most patients with hairy cell leukemia.[31] After a splenectomy, there is usually little or no change in the bone marrow, and virtually all patients have progressive disease within 12 to 18 months.

Sources: 31

Health professional · Treatment of Hairy Cell Leukemia / Treatment Options for Hairy Cell Leukemia

Interferon

Source: Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 21, 2025. Captured 2026-09-09.

Interferon alfa is no longer available because production has been halted.[32] According to the Hairy Cell Leukemia Foundation, ropeginterferon alfa-2b-njft is the best available preparation, but it is not FDA approved for hairy cell leukemia.

Sources: 32

Interferon is useful when treating hairy cell leukemia during pregnancy because it does not involve cytotoxic agents.

For patients · General Information About Hairy Cell Leukemia

Certain factors affect treatment options and prognosis (chance of recovery).

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

The treatment options depend on:

The number of hairy (leukemia) cells and healthy blood cells in the blood and bone marrow.

Whether the spleen is swollen.

Whether there are signs or symptoms of leukemia, such as infection.

Whether the leukemia has recurred (come back) after previous treatment.

Sources: recurred

The prognosis depends on:

Sources: prognosis

Whether the hairy cell leukemia does not grow or grows so slowly it does not need treatment.

Whether the hairy cell leukemia responds to treatment.

Sources: responds

Treatment often results in a long-lasting remission (a period during which some or all of the signs and symptoms of the leukemia are gone). If the leukemia returns after it has been in remission, re-treatment often causes another remission.

Sources: remission

For patients · Stages of Hairy Cell Leukemia

Sometimes hairy cell leukemia does not respond to treatment or comes back after treatment.

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

Refractory hairy cell leukemia is cancer that does not respond to treatment.

Sources: Refractory · respond

Recurrent hairy cell leukemia is cancer that has recurred (come back) after it has been treated.

Sources: Recurrent · recurred

For patients

Treatment Option Overview

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

There are different types of treatment for patients with hairy cell leukemia.

The following types of treatment are used:

The following types of treatment are used:

Watchful waiting

Chemotherapy

Targeted therapy

Surgery

New types of treatment are being tested in clinical trials.

Treatment for hairy cell leukemia may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up care may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with hairy cell leukemia.

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

Different types of treatment are available for patients with hairy cell leukemia. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: hairy cell leukemia · standard · clinical trials · research study · cancer

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Watchful waiting

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

Watchful waiting is closely monitoring a patient's condition, without giving any treatment until signs or symptoms appear or change.

Sources: Watchful waiting · signs · symptoms

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). The way the chemotherapy is given depends on the type and stage of the cancer being treated. Cladribine and pentostatin are anticancer drugs commonly used to treat hairy cell leukemia. These drugs may increase the risk of other types of cancer, especially Hodgkin lymphoma and non-Hodgkin lymphoma. Long-term follow-up for second cancers is very important. Bendamustine is another anticancer drug that is being studied to treat hairy cell leukemia.

Sources: Chemotherapy · drugs · injected · vein · systemic chemotherapy · stage · Cladribine · pentostatin · Hodgkin lymphoma · non-Hodgkin lymphoma · follow-up · second cancers · Bendamustine

Learn more about Drugs Approved for Hairy Cell Leukemia.

Sources: Drugs Approved for Hairy Cell Leukemia

For patients · Treatment Option Overview / The following types of treatment are used:

Targeted therapy

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells.

Sources: Targeted therapy

Monoclonal antibody therapy: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Rituximab is a type of monoclonal antibody that may be used to treat certain patients with hairy cell leukemia.

Sources: Monoclonal antibody · proteins · antibodies · infusion · toxins · radioactive · Rituximab

Other types of targeted therapies are being studied in the treatment of hairy cell leukemia, including:

Vemurafenib, dabrafenib, and trametinib are types of kinase inhibitors that block certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing.

Sources: Vemurafenib · dabrafenib · trametinib · mutated · BRAF

Ibrutinib is a type of targeted therapy that blocks a protein called Bruton's tyrosine kinase (BTK), which may help keep cancer cells from growing.

Sources: Ibrutinib

Learn more about Drugs Approved for Hairy Cell Leukemia.

Sources: Drugs Approved for Hairy Cell Leukemia

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

Splenectomy is a surgical procedure to remove the spleen.

Sources: Splenectomy · spleen

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview

Treatment for hairy cell leukemia may cause side effects.

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up care may be needed.

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Hairy Cell Leukemia

Source: Hairy Cell Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 23, 2025. Captured 2026-09-09.

Treatment of hairy cell leukemia may include:

Sources: hairy cell leukemia

Watchful waiting when possible.

Sources: Watchful waiting

Cladribine with or without rituximab.

Sources: Cladribine · rituximab

BRAF inhibitors (vemurafenib or dabrafenib) with or without rituximab or trametinib.

Sources: vemurafenib · dabrafenib · trametinib

Rituximab.

Pentostatin.

Sources: Pentostatin

Ibrutinib.

Sources: Ibrutinib

Repeat treatment with cladribine or pentostatin.

Bendamustine with rituximab.

Sources: Bendamustine

Splenectomy.

Sources: Splenectomy

Learn more about these treatments in the Treatment Option Overview

Sources: Treatment Option Overview

You and your doctor will discuss what treatment plan is best for you.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

NCT00586924 · COMPLETED · phase1

Hairy Cell Leukemia

ClinicalTrials.gov record

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

NCT00923013 · ACTIVE NOT RECRUITING · phase2

Hairy Cell Leukemia

ClinicalTrials.gov record

Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

NCT00924040 · TERMINATED · phase2

Hairy Cell Leukemia

ClinicalTrials.gov record

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

NCT01059786 · ACTIVE NOT RECRUITING · phase2

Hairy Cell Leukemia

ClinicalTrials.gov record

BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia

NCT01711632 · COMPLETED · phase2

Hairy Cell Leukemia

ClinicalTrials.gov record

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

NCT01829711 · COMPLETED · phase3

Leukemia, Hairy Cell

ClinicalTrials.gov record

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

NCT02362035 · COMPLETED · phase1, phase2

Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia,...

ClinicalTrials.gov record

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

NCT03010358 · COMPLETED · phase1, phase2

Anemia, B-Cell Prolymphocytic Leukemia, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma,...

ClinicalTrials.gov record

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

NCT03805932 · ACTIVE NOT RECRUITING · phase1

Hairy Cell Leukemia

ClinicalTrials.gov record

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

NCT05537766 · TERMINATED · phase2

Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt Lymphoma, Relapsed/Refractory Hairy Cell Leukemia

ClinicalTrials.gov record

Disease and treatment settings

Hairy Cell Leukemia

Disease and treatment setting

Hairy Cell Leukemia

Drug labels

Nipent

Label date 2026-07-01

INDICATIONS AND USAGE NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia,...

DailyMed label